It is becoming increasingly clear that NICE and IQWiG have very different concerns on the reimbursement front, but it is only a matter of time before IQWiG gets its teeth into cost-benefit analyses.
Continue reading "European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical Benefit, But Convergence May Come" »
Funding for private biotech companies in Europe declines 17% during 2011, while funding for public biotech companies falls 50%, although 2012 starts strongly.
Continue reading "Austerity Holds Back VC Investing in European Biotech Companies in 2011" »
Industry welcomed the initiatives, which included making National Health Service clinical data more widely available and strengthening NICE's role.
Continue reading "U.K. To Leverage NHS Data As Part Of Broader Stimulus Package, But Details Still Sketchy" »
German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.
Continue reading "Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe" »
Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.
Continue reading "AZ’s Brillinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward" »
A bill in the French upper house of parliament, the Senate, aimed at averting conflicts of interest in the pharmaceutical sector now has a section that could in fact encourage conflict by creating potentially painful class action cases against firms.
Continue reading "Rx Class Action Suits May Come To France In Response To Mediator Scandal" »
Amsterdam Molecular Therapeutics BV's potential gene therapy, Glybera (alipogene tiparvovec), may have been rejected for approval by Europe's top scientific advisory panel, CHMP, on Oct. 21, but the closeness of the vote - there was only one dissenting voice - suggests it won't be long before a gene therapy product clears the committee and reaches the European market.
Continue reading "Amsterdam Molecular Therapeutics Ends Glybera Development, Halves Workforce " »
Teva Pharmaceuticals Industries Ltd. has succeeded in piercing the market exclusivity surrounding GlaxoSmithKline PLC's inhaled asthma products with a "first-to-market" launch on Oct.7 in the U.K. of a salmeterol xinafoate inhaler.
Continue reading "Teva Launches Generic Salmeterol in the U.K. To Compete With GSK's Serevent " »
The Swedish government published on Sept. 22 a framework directive designed to revolutionize the pricing, reimbursement of and access to patent-protected pharmaceuticals.
Continue reading "Proposed Swedish Pharma Pricing Model Suggests VBP Is Not Enough To Control Costs " »
Germany's pharmaceutical sector restructuring law (AMNOG) is living up to the government's expectations by putting the brakes on the country's drug expenditure.
Continue reading "Success Of German Cost-Control Law Raises Prospect Of Further Cuts For Pharma " »